The third nervous system in the lung: physiology and clinical perspectives
are neither adrenergic nor cholinergic were described by Campbell in 1971. 4 Since then NANC nerves which relax airway smooth muscle have been found in several species, including man. 55 In these studies airway strips are mounted in an organ bath and stimulated by an electrical current that selectively activates nerves. In guinea pig tracheal strips electrical field stimulation produces an initial contraction that is blocked by the anticholinergic drug atropine and therefore due to acetylcholine release from cholinergic nerves. The initial contraction is followed by a relaxation, which is only partially inhibited by ,3 adrenergic blockers. 56 Thus, although a component of the inhibitory response is adrenergic, there is a component that is nonadrenergic. The nerve toxin tetrodotoxin abolishes these responses to field stimulation and proves that they are mediated by nerves (which must be postganglionic), and not due to a direct effect on smooth muscle. Thus guinea pig trachea appears to have excitatory cholinergic nerves and inhibitory nerves which are both adrenergic and non-adrenergic. In similar studies on human airway smooth muscle a cholinergic contractile component is also demonstrable, but the inhibitory response is unaffected by adrenergic blockade.78 This indicates, rather surprisingly, that there is no functional sympathetic innervation of human airway smooth muscle and that inhibitory nerves are non-adrenergic. The absence of sympathetic nerves in human airway smooth muscle is supported by histological studies showing an absence of adrenergic nerve terminals within smooth muscle,79 by studies showing a lack of effect of cocaine (a neuronal uptake inhibitor) on noradrenaline dose-response curves,'0 and by the lack of effect of tyramine (which directly releases noradrenaline from nerve terminals) on airway function in man." There are, of course, adrenergic receptors in airway smooth muscle,'2 and these are presumably regulated by circulating adrenaline.'3 NANC nerves appear to be the only neural inhibitory pathway in human airway smooth muscle from the trachea to the smallest bronchi,7 and for this reason there is particular interest in their physiological role and regulation.
NANC Electrical field stimulation of tracheobronchial preparations releases VIP into the bathing medium and the release is blocked by tetrodotoxin, indicating that VIP is derived from nerve stimulation.223' Furthermore, the amount of VIP released is related to the magnitude of NANC relaxation.3' Unfortunately no specific blocker of VIP is yet available, but prolonged incubation of airway smooth muscle with VIP reduces subsequent responses to VIP (tachyphylaxis) and also reduces the magnitude of NANC nerve relaxation in cats.2' Preincubation of guinea pig trachea with a specific antibody to VIP also reduces the NANC relaxation response.37
Taken together, all this evidence points strongly to VIP as a likely candidate for the role of neurotransmitter of non-adrenergic inhibitory nerves. Conclusive proof, particularly in human airways, awaits development of a specific blocker.
Other VIPergic nerves in lung VIPergic nerves may regulate other aspects of pulmonary function, since they are widely distributed within the lung. VIPergic nerves are closely associated with airway submuscosal glands27 32 Substance P and non-cholinergic excitatory nerves Substance P, an 11 amino acid peptide, is localised to afferent nerves in the airways of several species, including man.2748 Substance P immunoreactive nerves in the airway are found beneath and within the airway epithelium, around blood vessels, and to a lesser extent within airway smooth muscle. Treatment of animals with capsaicin, a pungent extract of red peppers, releases substance P from sensory nerves and depletes the lung of substance P.49 Substance P contracts airway smooth muscle of several species, including man.4850 Moreover, capsaicin is capable of inducing a similar contraction, indicating release of substance P from intrinsic nerves within airway smooth muscle.50 In rats substance P and capsaicin induce oedema of the airway mucosa by increasing vascular permeability, and depletion of substance P nerves by neonatal capsaicin pretreatment prevents irritants such as cigarette smoke from causing mucosal oedema, suggesting that substance P nerves mediate this effect.5' Substance P also stimulates airway mucus secretion.5' Electrical stimulation of guinea pig bronchi in vitro produces a component of bronchoconstriction which is not inhibited by atropine,5253 but which is blocked by a substance P antagonist.52 In human airways, however, this non-cholinergic non-adrenergic excitatory nervous pathway was found in only one out of eight airways tested.50 In man inhalation of capsaicin induces cough and transient bronchoconstriction which is seen in both normal and asthmatic subjects, 54 (,8 adrenergic) control. Although minor abnormalities in classical autonomic mechanisms have been found in asthma, they are insufficient to account for bronchial hyperreactivity.' The recent discovery of nonadrenergic inhibitory nerves in the airways has therefore raised the possibility that this nervous system is defective in asthma, particularly since it is the only neural inhibitory system in human airways. Non-adrenergic inhibitory nerves may exert a braking effect on bronchoconstriction, and a functional defect would presumably lead to exaggerated responses to constrictor stimuli. Unfortunately the absence of specific blocking drugs for these nerves makes it difficult to evaluate this possibility at present, although it seems likely that specific inhibitors of putative neurotransmitters such as VIP will be developed soon. There are analogies between asthma and other conditions in which there is abnormal smooth muscle control and in which abnormalities of peptidergic nerves have been found. In Hirschprung' s disease there is contraction of colonic smooth muscle and an absence of ganglia and peptidergic nerves in the colon wall.58 A similar reduction in VIPergic nerves has also been found in the wall of unstable bladders. 58 The demonstration of substance P containing nerves in human airways is also clinically relevant since this peptide can produce bronchoconstriction, bronchial mucosal oedema, and mucus hypersecretion, all of which are features of asthma. In human skin substance P produces a weal and flare 565 response when injected intradermally48 and causes the direct release of histamine from human skin mast cells in vivo (D Heavey et al, unpublished observations). If this were to occur in the airway then stimulation of substance P nerves could lead to a local axon reflex, with release of substance P, resulting in bronchial smooth muscle contraction and mucosal oedema. It is tempting to speculate that in asthma these substance P nerves may be sensitised by inflammation, or that airway mast cells may be more sensitive to substance P, so that constrictor responses become exaggerated.
The clinical implications of NANC innervation in the lungs are only now being appreciated, but abnormal function of non-adrenergic inhibitory nerves (which are probably VIPergic and PHIergic) or of non-cholinergic excitatory nerves (probably substance P containing) could underly bronchial hyperreactivity in asthma. NANC nerves also influence airway mucus secretion and pulmonary vascular tone, so that there are important implications for chronic bronchitis and for pulmonary vascular disease. Future 
